Bryant H, Brasher P
Division of Epidemiology, Prevention and Screening, Alberta Cancer Board, Calgary, Canada.
N Engl J Med. 1995 Jun 8;332(23):1535-9. doi: 10.1056/NEJM199506083322302.
In 1992, Berkel and colleagues reported in the Journal the results of their study of the potential association of breast augmentation and breast cancer. The study reported that women who had breast augmentation had a significantly lower subsequent risk of breast cancer (P < 0.01) than the general population, with a standardized incidence ratio of 0.48 overall. Assuming a 10-year induction period (that is, assuming that cancers found within 10 years of the augmentation might have been the result of a process begun before surgery and therefore should not be considered), the reported standardized incidence ratio was 0.16. Problems were later identified involving some of the study methods. This paper reports a second analysis of these data.
We used a data set from Alberta Health Care to identify eligible women with bilateral breast augmentation. Using a combination of deterministic and probabilistic methods, we linked this data set to the Alberta Cancer Registry to identify subsequent breast cancers that developed during the study period. Multiple estimates of standardized incidence ratios were calculated on the basis of differing study-eligibility dates, induction periods, and types of breast-cancer (invasive only or invasive plus in situ).
The reanalysis found substantial differences in the numbers of person-years at risk, resulting in higher standardized incidence ratios than in the original analysis. The final ratios for all breast cancers, with October 1, 1973, used as the starting date of the study, were 0.76 (95 percent confidence interval, 0.55 to 1.02), 0.85 (95 percent confidence interval, 0.58 to 1.19), and 0.68 (95 percent confidence interval, 0.32 to 1.25) for induction periods of 0, 5, and 10 years, respectively. None of these standardized incidence ratios were significantly different from 1.
On the basis of this reanalysis, the incidence of breast cancer among the women who had breast augmentation could not be said to be either significantly higher or lower than that among the general population over the period during which this cohort was followed.
1992年,伯克等人在《杂志》上报告了他们关于隆胸与乳腺癌潜在关联的研究结果。该研究报告称,隆胸女性随后患乳腺癌的风险显著低于一般人群(P<0.01),总体标准化发病率为0.48。假设诱导期为10年(即假设在隆胸后10年内发现的癌症可能是手术前就已开始的过程导致的,因此不应考虑在内),报告的标准化发病率为0.16。后来发现该研究的一些方法存在问题。本文报告了对这些数据的二次分析。
我们使用来自艾伯塔省医疗保健机构的数据集来确定符合条件的双侧隆胸女性。通过确定性和概率性方法相结合,我们将该数据集与艾伯塔省癌症登记处相链接,以确定研究期间发生的后续乳腺癌病例。根据不同的研究入选日期、诱导期和乳腺癌类型(仅浸润性或浸润性加原位癌)计算了标准化发病率的多种估计值。
重新分析发现,风险人年数存在显著差异,导致标准化发病率高于原分析。以1973年10月1日作为研究起始日期,所有乳腺癌的最终发病率在诱导期为0年、5年和10年时分别为0.76(95%置信区间为0.55至1.02)、0.85(95%置信区间为0.58至1.19)和0.68(95%置信区间为0.32至1.25)。这些标准化发病率均与1无显著差异。
基于此次重新分析,在对该队列进行随访的期间内,隆胸女性中乳腺癌的发病率与一般人群相比,既不能说显著更高,也不能说显著更低。